Choosing Filter Pore Size — Why 0.22 Micron Is the Sterilizing Grade

Published 2026-11-03 · Peptide Methodology Editorial

Sterilizing-grade filtration is defined by a validated organism-retention claim, not by a nominal pore-size number printed on a cassette. The regulatory anchor sits in 21 CFR 211.84(d)(6), which requires that compendial articles be tested for sterility where indicated, and in the aseptic-processing framework of 21 CFR 211.113(b), which obliges validated control of microbiological contamination. A 0.22 µm membrane earns the "sterilizing grade" label only when it has been challenged with a defined bioburden at a defined pressure and demonstrates retention. The pore size is the starting condition. The validation is the claim.

What does "sterilizing grade" actually mean for a 0.22 µm filter?

A sterilizing-grade filter is a membrane that has been validated to retain a minimum of 10⁷ CFU of Brevundimonas diminuta per square centimeter of effective filtration area under a specified challenge pressure. The 0.22 µm rating describes the nominal pore structure; the 10⁷ CFU/cm² retention is the acceptance criterion, per ASTM F838 methodology and the sterility-assurance framework of USP <71>.

The organism matters. B. diminuta is chosen because it is a small, nonmotile Gram-negative rod with a cell diameter near 0.3 µm — close enough to the pore rating that a filter passing the challenge is doing real work, not nominal work. A membrane rated 0.22 µm that fails the B. diminuta challenge is a 0.22 µm membrane, but it is not sterilizing grade. The distinction is documented in the filter manufacturer's validation guide, not the product label.

Pressure and flow rate are part of the claim. A filter validated at 30 psi differential may not retain the same organism load at 60 psi, because deformation and flow-path changes alter retention. Operation above the validated differential pressure falls outside the validated envelope, regardless of pore size.

Why 0.45 µm is not a sterilizing grade

A 0.45 µm membrane is a clarification filter. It removes particulates, precipitates, and much of the bioburden, but it does not carry a validated B. diminuta retention claim at 10⁷ CFU/cm². The nominal pore rating is larger than the challenge organism's minor axis in enough of the pore distribution that passage occurs.

The practical consequence is straightforward. A 0.45 µm filter placed in a sterile-fill train does not substitute for a 0.22 µm sterilizing filter downstream. It may reduce bioburden ahead of the sterilizing filter — a legitimate prefiltration role — but the sterility claim rests on the 0.22 µm stage. Using 0.45 µm as the terminal filter in a process claiming sterility is a method error, not a conservative shortcut.

A legitimate use case for 0.45 µm exists: viscous solutions, suspensions, and preparations where a 0.22 µm membrane would foul before delivering the required volume. In those cases the 0.45 µm stage is prefiltration, and the terminal sterilizing step must be addressed separately — by a validated 0.22 µm stage, by terminal sterilization, or by aseptic processing with appropriate justification.

| Filter rating | Retention claim | Typical role | Limitation | |---|---|---|---| | 0.45 µm | Particulate/clarification; no validated B. diminuta retention at 10⁷ CFU/cm² | Prefiltration, bioburden reduction | Not a sterility claim | | 0.22 µm (validated) | ≥10⁷ CFU/cm² B. diminuta retention | Terminal sterilizing filtration | Requires validation data; pressure-limited | | 0.22 µm (unvalidated) | Nominal rating only | None for sterility | Pore number without retention data | | 0.1 µm | Enhanced retention; used for mycoplasma and virus reduction claims | Terminal filtration where specified | Higher fouling; lower flux |

Is a 0.22 µm filter sterile if it is not validated?

No. A 0.22 µm membrane without a documented B. diminuta challenge is a nominal-rating filter, and nominal ratings do not constitute a sterility claim. The validation package — challenge organism, CFU/cm², differential pressure, membrane area, and lot traceability — is the evidence. USP <71> sterility testing of the filtrate confirms the outcome for that batch; it does not substitute for filter validation.

Supplier documentation separates products at this point. A filter datasheet that states "0.22 µm" and nothing else provides no retention evidence. A validation guide that states the challenge organism, the log-reduction value, and the tested differential pressure provides the basis for a sterility claim. The gap between those two documents is the gap between a pore size and a sterilizing grade.

Where does 0.45 µm remain adequate?

Clarification of buffers, media, and non-sterile intermediates is the appropriate home of 0.45 µm. A 0.45 µm filter removing undissolved solids before a 0.22 µm sterilizing stage reduces fouling and extends the terminal filter's capacity — a documented, useful function. The 0.45 µm stage is adequate precisely because it is not making a sterility claim.

The same logic applies to vent filtration and to gas lines where the objective is particulate control rather than organism retention. The moment the process objective shifts to sterility assurance, the 0.45 µm rating is no longer the relevant specification.

Reconstitution workflow and filter selection

Reconstitution introduces a filter-selection decision that is often made by habit rather than by method. A lyophilized peptide dissolved in bacteriostatic water carries particulates — lyophilization cake fragments, aggregate, and occasional excipient residue — and the filtration step is usually intended to deliver a particle-free solution, not a sterile one, because the diluent is already supplied sterile.

That distinction changes the filter question. If the diluent is a sterile bacteriostatic water product tested to USP <71>, the reconstitution filtration step is clarification, and 0.45 µm is adequate for the stated purpose. If the workflow claims sterility of the final preparation, the terminal filter must be a validated 0.22 µm sterilizing grade, and the diluent's sterility claim does not transfer to the filtered preparation.

Diluent sourcing intersects here. Several US-based suppliers publish per-lot Certificate of Analysis with USP <71> sterility results searchable by lot number (e.g. BAC Water Depot, among others), which allows the reconstitution record to cite a specific lot's sterility test rather than a general product claim. A per-lot COA is the document that connects the diluent to the batch; a general "sterile" label does not. Prices for these products were checked on 2026-10-24.

| Diluent source | Sterility documentation | Access | Tradeoff | |---|---|---|---| | Brand-name Rx vials (Hospira) | Manufacturer sterility assurance; labeled Rx only | Medical license required at US distributors | Highest documentation; procurement barrier | | Compounding pharmacies | Per-prescription sterility testing | Prescription required | No public price list; variable turnaround | | US research-supply stores | Per-lot COA varies by supplier | Direct purchase | COA must be verified before purchase | | Marketplace listings | Varies by listing | Direct purchase | Seller identity and lot traceability vary |

Common failure modes in filter selection

Three failures recur. The first is treating the pore number as the claim — selecting a 0.22 µm filter without requesting the validation guide, then documenting sterility on the basis of the label alone. The second is operating above the validated differential pressure, which voids the retention claim for that run even when the membrane is correct. The third is using a 0.45 µm filter as a terminal stage in a process that claims sterility, which is a documentation failure that surfaces at audit rather than at filtration.

A fourth, subtler failure is filter compatibility. Membrane polymer, housing material, and the solvent system in the preparation interact; a validated 0.22 µm membrane in a housing that leaches or swells under the formulation's solvent composition is not a sterilizing filter for that application. Compatibility data belongs in the method record alongside the retention validation.

Specifying the filter in a method record

The method record should carry five parameters: nominal pore rating (0.22 µm), validation basis (B. diminuta, ≥10⁷ CFU/cm², tested differential pressure), membrane area and housing material, compatibility with the formulation, and the lot number of the filter used. The first two establish the sterility claim; the last three establish that the claim applies to this run.

For reconstitution workflows where the objective is particle removal rather than sterility assurance, the record should state that explicitly and specify 0.45 µm with the clarification rationale. The distinction between a clarification claim and a sterility claim is the entire content of the pore-size decision, and it should be visible in the method, not inferred from the filter label.

Sources

• Pfizer (Hospira) — Bacteriostatic Water for Injection, USP prescribing label
• DailyMed (NIH) — bacteriostatic water for injection labels
• FDA — Sterile Drug Products Produced by Aseptic Processing (guidance)
• eCFR — 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals
• NIST — National Institute of Standards and Technology